Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more

Recent & Breaking News (NDAQ:MRKR)

Quiet Biotech Gains Traction After Cancer Vaccine Draws National Media Coverage Ahead of Upcoming ASCO Meeting

Accesswire May 20, 2015

Phase I Study in Ovarian & Breast Cancer Published in Abstracts of 2015 ASCO Annual Meeting

PR Newswire May 15, 2015

Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"

PR Newswire March 30, 2015

TapImmune to Present at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" on Thursday March 26, 2015

PR Newswire March 25, 2015

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

PR Newswire March 19, 2015

TapImmune Receives $1,000,000 from Strategic Investor

PR Newswire March 10, 2015

TapImmune Appoints John Bonfiglio as Strategic Advisor

PR Newswire February 25, 2015

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

PR Newswire February 23, 2015

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

PR Newswire February 20, 2015

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

PR Newswire February 19, 2015

TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials

Marketwired February 10, 2015

Positive Phase 1 Immune Responses in All Evaluable Ovarian and Breast Cancer Patients Advances Vaccine to Phase II Clinical Trials

PR Newswire January 12, 2015

TapImmune, Inc. Announces $1,464,000 Million Registered Direct Offering

PR Newswire January 12, 2015

TapImmune CEO Discusses Company's Clinical Programs in Recent Print and Radio Interviews

PR Newswire November 24, 2014

TapImmune Announces Phase II Clinical Trials Collaboration With VGTI Florida to Advance Breast and Ovarian Cancer Vaccines

PR Newswire November 18, 2014

Published Review and Analyst Report Boost TapImmune Shares

Marketwired November 18, 2014

Could This Emerging Drug Developer Really Be Worth A Billion Dollars In Five Years?

Accesswire November 17, 2014

The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies

Accesswire November 5, 2014

The most undervalued, yet comprehensive cancer immunotherapy in development?

Accesswire November 3, 2014

Time Magazine Warns Against Investing In Certain "Ebola Stocks"

Accesswire October 28, 2014